Research programme: transdermal anti-emetic therapy - NexMed

Drug Profile

Research programme: transdermal anti-emetic therapy - NexMed

Alternative Names: Anti-emetic patch - NexMed; NM 10065; NM 10066

Latest Information Update: 11 Feb 2008

Price : $50

At a glance

  • Originator NexMed
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nausea and vomiting; Pain

Most Recent Events

  • 30 Aug 2005 NM 100065 is still in active development for Emesis
  • 25 May 2004 Discontinued - Preclinical for Pain in USA (Topical)
  • 16 Sep 2003 Preclinical trials in Emesis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top